Thrive Capital Partners VII Growth, L.P.'s Form 4 filing
Oscar Health, Inc. (OSCR) · filed Aug 24, 2021
- Accession no.
- 0000899243-21-034081
- Filed
- Aug 24, 2021, 8:43 PM ET
- Trade date
- Aug 20-24, 2021
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions. Open-market purchases total $16.2M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Thrive Capital Partners VII Growth, L.P.CIK 0001841736 | 10% Owner |
| Claremount VII Associates, L.P.CIK 0001841808 | 10% Owner |
| Thrive Partners VII GP, LLCCIK 0001877733 | 10% Owner |
| Thrive Partners VII Growth GP, LLCCIK 0001877735 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 20, 2021 | Class A Common Stock | PPurchaseAcquired | +68,042 | $13.41F1 | +$912,592.91 | 68,542 | Indirect | |
| Aug 23, 2021 | Class A Common Stock | PPurchaseAcquired | +125,900 | $13.01F3 | +$1,638,009.36 | 194,442 | Indirect | |
| Aug 24, 2021 | Class A Common Stock | PPurchaseAcquired | +1,074,342 | $12.69 | +$13,633,399.98 | 1,268,784 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents (i) 67,232 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 810 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $13.12 to $13.53, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18.
Referenced by the price of 1 transaction in Table I.
- F3
Represents (i) 124,401 shares purchased by Thrive VII Growth and (ii) 1,499 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $12.83 to $13.29, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18.
Referenced by the price of 1 transaction in Table I.